Clonidine HCL

Phase 3Small molecule

WWake Forest University Health Sciences

Clonidine HCL is one of 60 small molecule programs targeting Opioid Dependence. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid DependenceActive, not recruiting

Neonatal Abstinence SyndromeActive, not recruiting

Renal CarcinomaRecruiting

Opioid DependencePhase 2/Phase 3

Active, not recruiting

Neonatal Abstinence SyndromePhase 2

Active, not recruiting

Renal CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

59 competitors in Opioid Dependence

#DrugCompanyPhaseTrials

Epidiolex

Keppra

Actos

Victoza

Revia

6 6

Ultram

Narcan

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—9

Ketalar

AAultman Health Foundation

Approved

—10

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Renal Carcinoma

NCT07092566

Clinical

Trials by Indication[1]

Neonatal Abstinence Syndrome1 trial

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00510016·80 enrolled

Opioid Dependence1 trial

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

Terminated·JJohns Hopkins University·Phase 2/3·NCT01360450·12 enrolled

Renal Carcinoma1 trial

Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial

Recruiting·WWake Forest University Health Sciences·Phase 3·NCT07092566·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Clonidine HCL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clonidine HCL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clonidine HCL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWake Forest University Health Sciences

Clonidine HCL

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neonatal Abstinence Syndrome1 trial

Opioid Dependence1 trial

Renal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News